The Novimed Journal · Clinical research
Linguistic Validation in Rare-Disease Clinical Trials

Rare-disease linguistic validation requires a deliberate plan for preserving assessment meaning when populations are small, symptoms may be unfamiliar and recruitment is difficult. Limited access to respondents should be documented and addressed through a justified methodology, rather than treated as permission to assume comprehension.
Begin with the measurement question
A rare-disease programme may involve heterogeneous symptoms, different stages of disease and widely dispersed participants. Clarify which experience the assessment is intended to capture and who will report it. A patient’s report of an internal symptom, a caregiver’s observation and an administrator’s performance task are different sources of evidence.
FDA’s fit-for-purpose approach is relevant because the context of use governs what evidence is needed. For translation planning, describe the intended population, concept and mode clearly. Avoid assuming that an instrument appropriate for one disease stage or respondent group remains appropriate after changes to language, administration or reporting role.
Map each evidence source to the question it can answer
NovimedGroup’s November post calls for deeper, better-connected evidence when populations are small and dispersed. For language planning, this means making the purpose of each source explicit. Concept-elicitation interviews explore experiences that matter. Cognitive debriefing investigates understanding of specified wording. Patient-preference research concerns choices or trade-offs under its own design. These activities may inform the same programme, but their findings are not interchangeable.
Prepare a compact evidence map with the intended claim, relevant respondents, language-country context, source material, limitations and decision owner. For example, a caregiver interview may describe observable interruptions to daily routines. It does not directly establish how a patient interprets an internal-symptom item or which treatment trade-offs that patient would accept. Preserve those distinctions when combining reports or translating a summary for another team.
FDA’s PFDD Guidance 3 concerns selecting, developing or modifying assessments for a defined use. It does not make a small qualitative exercise sufficient for every measurement claim. Treat the language evidence map as an editorial planning aid within that wider programme. The responsible COA and statistical specialists should determine which conclusions require additional evidence, and which limitations prevent a proposed interpretation.
Clarify unfamiliar symptom language
Some symptoms have a familiar clinical term but no equally familiar everyday expression. Other experiences may be described differently across communities. Give translators useful concept definitions, including what the item includes and excludes. Ask local specialists to distinguish a missing everyday term from a concept that is understood but normally expressed descriptively.
A hypothetical item about fatigue illustrates the problem: an alternative that means sleepiness may sound natural while narrowing the intended experience. The solution is not automatically to add a long clinical definition. Discuss the concept with the instrument owner, develop appropriate wording and investigate how intended respondents interpret it.
A practical reading lens
Define the concept
Review the evidence
Record the decision
Plan recruitment before the language schedule is fixed
Recruitment can become the critical dependency in a rare-disease project. Discuss feasibility early, including the countries, language variants, eligibility criteria and practical participation needs. Identify which organizations or clinical contacts may support recruitment through approved arrangements. Do not promise a fixed interview schedule without understanding those dependencies.
Where the intended sample is difficult to reach, escalate the constraint to the sponsor and relevant methodological stakeholders. A revised plan should explain what evidence can be obtained, what remains uncertain and how that affects interpretation. Avoid presenting an alternative population as equivalent merely because recruitment is easier.
Reduce avoidable participation burden
Interview length, travel, screen use and repeated questioning can be demanding for people with significant symptoms or impairments. Plan breaks, accessible materials and scheduling appropriate to the population. These accommodations should help people participate without changing the intended response task in an undocumented way.
If assistance is needed, define its boundaries. Help with a device may be compatible with the study plan; explaining an item or choosing a response for the participant changes the evidence. Record the type of support provided so reviewers can distinguish language comprehension from the effects of assistance.
Treat caregiver perspectives carefully
Caregivers can explain routines and observable behaviours, but they may not know the patient’s internal experience. When a measure is an ObsRO, wording should preserve the observational task. When it is a PRO, a caregiver’s interpretation should not silently replace the patient’s response. These boundaries deserve explicit discussion in both translation and interview planning.
In paediatric or communication-limited populations, reporting roles may be especially complex. The translation team should work from the approved assessment strategy rather than independently redesigning it. Questions about who can report a concept should be escalated to the sponsor and instrument owner, with the resulting decision reflected in all language versions.
Make qualitative evidence transparent
A small number of interviews can identify meaningful language issues, but the report should describe who participated and what the findings can support. Avoid using percentages to imply population-level certainty from a small qualitative exercise. Present item-level observations, disagreements, revisions and remaining questions in a form that supports reasoned review.
If no participant raises a problem, consider whether the guide actually probed the relevant distinction. Silence is not always evidence of understanding. Reviewers should be able to see how the recall period, response choices and difficult concepts were explored. Document deviations from the plan and the rationale for accepting or addressing them.
Coordinate clinical, linguistic and implementation expertise
Rare-disease terminology may require clinical clarification, but clinicians and patients contribute different perspectives. The clinician helps assess medical meaning; the intended respondent provides evidence about comprehension and reporting. A linguist connects those perspectives to the target language and the instrument’s conceptual boundaries.
Electronic implementation adds further questions, particularly where vision, dexterity, cognition or fatigue affects interaction. Review the actual presentation and coordinate relevant usability and technical work. Do not assume that a linguistically approved file remains equally usable when text is reduced, split across screens or placed behind additional navigation.
Make disagreement across sources visible
Consider a hypothetical rare neuromuscular condition in which patients describe an activity as possible but exhausting, while caregivers report that the activity is usually completed. Both accounts may be accurate because they concern different aspects of the experience. A translated summary that compresses both into normal functioning would erase the distinction. Return to the assessment concept and the reporting role before deciding what each observation contributes.
In a multilingual project, also ask whether a difference reflects the population, the interview prompt, the translation or the mode of administration. A small number of accounts usually cannot distinguish those possibilities by itself. Retain competing explanations, seek an appropriate clarification and document whether it changes the interpretation. Do not resolve disagreement by choosing the most fluent translated account or treating the majority wording as necessarily correct.
A useful review record names the question, describes the conflicting observations, identifies the versions and respondent roles, and states the resulting action. The action may be a source query, a targeted interview probe, a controlled wording revision or an explicit limitation. These examples illustrate a reasoning process; they are not findings from a trial or instructions to redesign a licensed measure without authorization.
Choose deeper evidence without adding unnecessary burden
Deeper listening should mean more relevant questions and better interpretation, not simply longer interviews. Use the concept map and unresolved language questions to focus the guide. Coordinate requests across teams so participants are not repeatedly asked for the same information without a clear purpose. Where existing material is considered for reuse, check consent, provenance, version and suitability for the current question.
Describe who was reached and who was not, including language, disease-stage and access limitations relevant to interpretation. Protect confidentiality when small communities make people identifiable through combinations of details. A report can explain the evidence gap without publishing an individual’s detailed history. The handover should show the approved decisions, remaining uncertainties and responsibility for follow-up rather than imply that a complete set of documents creates certainty.
Use technology to organize uncertainty
A controlled workflow can make recruitment dependencies, source queries and review decisions visible. AI may help prepare comparisons or organize documentation, but limited language data and uncommon symptom concepts can make confident model output particularly misleading. Require the system to preserve uncertainty and route questions to people with the relevant expertise.
Dr. Matani’s public discussion of rare-disease linguistic validation emphasizes protecting meaning despite small populations. The operational recommendation is to document what is known, what was tested and what still requires judgment. For a project brief, provide the disease context, instrument, respondent type, locales and recruitment constraints so the validation plan can be discussed realistically.
Sources and editorial scope
Updated 9 November 2026 from first-party LinkedIn discussions. Practical evidence maps, workflows and scenarios are editorial recommendations, not study findings. Published adaptations and FDA guidance retain their own scope; no claim is made about unpublished conference results or regulatory acceptance.
A worksheet for your next project
Capture the instrument version, language-country pairs, review responsibilities and delivery evidence before agreeing the scope.
Download the project brief (plain text)Continue the conversation
Related on LinkedIn
The discussion connects small populations with careful listening, distinct evidence sources and transparent uncertainty.
NovimedGroup on evidence depth in rare-disease research ↗Put the discussion into practice
Discuss your COA/eCOA project
Explore our linguistic validation services and agree the languages, review stages and documentation your project needs.
Request project support →